Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma

Francesca Marino-Merlo, Antonio Mastino, Sandro Grelli, Olivier Hermine, Ali Bazarbachi, Beatrice Macchi

Research output: Contribution to journalReview article

Abstract

Human T cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T cell leukemia/lymphoma (ATL), HTLV-1 associated myelopathy (HAM/TSP), and of a number of inflammatory diseases with an estimated 10-20 million infected individuals worldwide. Despite a number of therapeutic approaches, a cure for ATL is still in its infancy. Conventional chemotherapy has short-term efficacy, particularly in the acute subtype. Allogeneic stem cell transplantation offers long-term disease control to around one third of transplanted patients, but few can reach to transplant. This prompted, over the past recent years, the conduction of a number of clinical trials using novel treatments. Meanwhile, new data have been accumulated on biological and molecular bases of HTLV-1 transforming and infecting activity. These data offer new rational for targeted therapies of ATL. Taking into account the double-face of ATL as an hematologic malignancy as well as a viral infectious disease, this Mini-Review seeks to provide an up-to-date overview of recent efforts in the understanding of the mechanisms involved in already used therapeutic regimens showing promising results, and in selecting novel drug targets for ATL.

Original languageEnglish
Article number925
JournalFrontiers in Microbiology
Volume9
DOIs
Publication statusPublished - May 9 2018

Fingerprint

Adult T Cell Leukemia Lymphoma
Drug Delivery Systems
Deltaretrovirus
Spinal Cord Diseases
Stem Cell Transplantation
Virus Diseases
Hematologic Neoplasms
Therapeutics
Communicable Diseases
Clinical Trials
Transplants
Drug Therapy
Pharmaceutical Preparations

Cite this

Marino-Merlo, F., Mastino, A., Grelli, S., Hermine, O., Bazarbachi, A., & Macchi, B. (2018). Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma. Frontiers in Microbiology, 9, [925]. https://doi.org/10.3389/fmicb.2018.00925

Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma. / Marino-Merlo, Francesca; Mastino, Antonio; Grelli, Sandro; Hermine, Olivier; Bazarbachi, Ali; Macchi, Beatrice.

In: Frontiers in Microbiology, Vol. 9, 925, 09.05.2018.

Research output: Contribution to journalReview article

Marino-Merlo, F, Mastino, A, Grelli, S, Hermine, O, Bazarbachi, A & Macchi, B 2018, 'Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma', Frontiers in Microbiology, vol. 9, 925. https://doi.org/10.3389/fmicb.2018.00925
Marino-Merlo F, Mastino A, Grelli S, Hermine O, Bazarbachi A, Macchi B. Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma. Frontiers in Microbiology. 2018 May 9;9. 925. https://doi.org/10.3389/fmicb.2018.00925
Marino-Merlo, Francesca ; Mastino, Antonio ; Grelli, Sandro ; Hermine, Olivier ; Bazarbachi, Ali ; Macchi, Beatrice. / Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma. In: Frontiers in Microbiology. 2018 ; Vol. 9.
@article{002da0708dbb4cb19a69d3d3e1951501,
title = "Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma",
abstract = "Human T cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T cell leukemia/lymphoma (ATL), HTLV-1 associated myelopathy (HAM/TSP), and of a number of inflammatory diseases with an estimated 10-20 million infected individuals worldwide. Despite a number of therapeutic approaches, a cure for ATL is still in its infancy. Conventional chemotherapy has short-term efficacy, particularly in the acute subtype. Allogeneic stem cell transplantation offers long-term disease control to around one third of transplanted patients, but few can reach to transplant. This prompted, over the past recent years, the conduction of a number of clinical trials using novel treatments. Meanwhile, new data have been accumulated on biological and molecular bases of HTLV-1 transforming and infecting activity. These data offer new rational for targeted therapies of ATL. Taking into account the double-face of ATL as an hematologic malignancy as well as a viral infectious disease, this Mini-Review seeks to provide an up-to-date overview of recent efforts in the understanding of the mechanisms involved in already used therapeutic regimens showing promising results, and in selecting novel drug targets for ATL.",
author = "Francesca Marino-Merlo and Antonio Mastino and Sandro Grelli and Olivier Hermine and Ali Bazarbachi and Beatrice Macchi",
year = "2018",
month = "5",
day = "9",
doi = "10.3389/fmicb.2018.00925",
language = "English",
volume = "9",
journal = "Frontiers in Microbiology",
issn = "1664-302X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Future Perspectives on Drug Targeting in Adult T Cell Leukemia-Lymphoma

AU - Marino-Merlo, Francesca

AU - Mastino, Antonio

AU - Grelli, Sandro

AU - Hermine, Olivier

AU - Bazarbachi, Ali

AU - Macchi, Beatrice

PY - 2018/5/9

Y1 - 2018/5/9

N2 - Human T cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T cell leukemia/lymphoma (ATL), HTLV-1 associated myelopathy (HAM/TSP), and of a number of inflammatory diseases with an estimated 10-20 million infected individuals worldwide. Despite a number of therapeutic approaches, a cure for ATL is still in its infancy. Conventional chemotherapy has short-term efficacy, particularly in the acute subtype. Allogeneic stem cell transplantation offers long-term disease control to around one third of transplanted patients, but few can reach to transplant. This prompted, over the past recent years, the conduction of a number of clinical trials using novel treatments. Meanwhile, new data have been accumulated on biological and molecular bases of HTLV-1 transforming and infecting activity. These data offer new rational for targeted therapies of ATL. Taking into account the double-face of ATL as an hematologic malignancy as well as a viral infectious disease, this Mini-Review seeks to provide an up-to-date overview of recent efforts in the understanding of the mechanisms involved in already used therapeutic regimens showing promising results, and in selecting novel drug targets for ATL.

AB - Human T cell leukemia virus type 1 (HTLV-1) is the etiological agent of adult T cell leukemia/lymphoma (ATL), HTLV-1 associated myelopathy (HAM/TSP), and of a number of inflammatory diseases with an estimated 10-20 million infected individuals worldwide. Despite a number of therapeutic approaches, a cure for ATL is still in its infancy. Conventional chemotherapy has short-term efficacy, particularly in the acute subtype. Allogeneic stem cell transplantation offers long-term disease control to around one third of transplanted patients, but few can reach to transplant. This prompted, over the past recent years, the conduction of a number of clinical trials using novel treatments. Meanwhile, new data have been accumulated on biological and molecular bases of HTLV-1 transforming and infecting activity. These data offer new rational for targeted therapies of ATL. Taking into account the double-face of ATL as an hematologic malignancy as well as a viral infectious disease, this Mini-Review seeks to provide an up-to-date overview of recent efforts in the understanding of the mechanisms involved in already used therapeutic regimens showing promising results, and in selecting novel drug targets for ATL.

U2 - 10.3389/fmicb.2018.00925

DO - 10.3389/fmicb.2018.00925

M3 - Review article

C2 - 29867836

VL - 9

JO - Frontiers in Microbiology

JF - Frontiers in Microbiology

SN - 1664-302X

M1 - 925

ER -